Medical Oncology

COG

Questions discussed in this category

In a patient with HR B ALL and severe pancreatitis due to peg-asparaginase, how do you assess the impact of peg discontinuation on risk of relapse?

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

2 Answers available

Papers discussed in this category

The Lancet. Oncology, 2017-09

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.

J Clin Oncol, 2020 Apr 10

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Related Topics in Medical Oncology